Cargando…

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study

BACKGROUND: Advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients without driver gene mutations are usually treated with immune checkpoint inhibitors (ICIs) plus pemetrexed as maintenance therapy after first-line ICIs plus 4–6 cycles of pemetrexed/platinum. Some patients in the real w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Xiaodong, Shi, Zhiyong, Shao, Lan, Zhang, Yuxin, Zhang, Yiping, Song, Zhengbo, Wang, Wenxian, Lou, Guangyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128194/ https://www.ncbi.nlm.nih.gov/pubmed/35606756 http://dx.doi.org/10.1186/s12885-022-09674-2

Ejemplares similares

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
por: Wang, Wenxian, et al.
Publicado: (2022)

The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
por: Wang, Wenxian, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
por: Gu, Xiaodong, et al.
Publicado: (2023)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2015)

Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
por: Li, Jianqiang, et al.
Publicado: (2020)

Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy
por: Song, Zhengbo, et al.
Publicado: (2016)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
por: Lu, Shao-Lun, et al.
Publicado: (2016)

Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer
por: Xu, Yi-Bing, et al.
Publicado: (2021)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Safety and Efficacy of Pemetrexed in Maintenance Therapy of Non-Small Cell Lung Cancer
por: Velez, Michel, et al.
Publicado: (2012)

Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
por: Gu, Xiaodong, et al.
Publicado: (2022)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

A long‐term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced non‐squamous non‐small cell lung cancer
por: Furugen, Makoto, et al.
Publicado: (2020)

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
por: Belani, Chandra P, et al.
Publicado: (2014)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis
por: Wang, Wenxian, et al.
Publicado: (2018)

Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma translocation: A case report
por: Wang, Wenxian, et al.
Publicado: (2015)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
por: Ricciardi, Serena, et al.
Publicado: (2009)

Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design
por: Lal, Rohit, et al.
Publicado: (2013)

Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial
por: He, Zhen, et al.
Publicado: (2022)

Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer
por: Wang, Wenxian, et al.
Publicado: (2018)

Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety
por: Shao, Lan, et al.
Publicado: (2022)

Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study
por: Wang, Wenxian, et al.
Publicado: (2018)

Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
por: Zhong, R., et al.
Publicado: (2021)

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
por: Mubarak, Nabil, et al.
Publicado: (2012)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
por: Kasai, Takashi, et al.
Publicado: (2023)

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
por: Yoon, Joon‐Young, et al.
Publicado: (2019)

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
por: Garrido, Pilar, et al.
Publicado: (2017)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
por: Patil, Vijay, et al.
Publicado: (2019)

HER2 mutations in Chinese patients with non-small cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2016)

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
por: Song, Zhengbo, et al.
Publicado: (2022)

Correlation Between Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphisms and Pemetrexed Chemotherapy Efficacy/Toxicity in Non-Squamous Non-Small Cell Lung Cancer
por: Lan, Gaochen, et al.
Publicado: (2017)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hjh0n0mujdocduhi65rabf5grr